WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to announce the appointment of Dr. Almira Chabi, MD, EGMP to its Board of Directors, effective November 24, 2023. Dr. Chabi.
Senate Majority Leader Chuck Schumer has announced that the Senate will seek to address national security and education concerns about artificial intelligence (AI) programs, such as ChatGPT.
Senate Majority Leader Chuck Schumer has announced that the Senate will seek to address national security and education concerns about artificial intelligence (AI) programs, such as ChatGPT.